Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Liminatus Pharma Inc. (LIMN) had Consolidated Net Income/Loss of $0.11M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$0.11M |
|
-- |
|
-- |
|
$1.12M |
|
$-1.12M |
|
$1.23M |
|
$0.11M |
|
$0.11M |
|
$0.11M |
|
$0.11M |
|
|
Consolidated Net Income/Loss |
$0.11M |
$0.11M |
|
$-1.12M |
|
$-1.12M |
|
23.30M |
|
23.30M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.78M |
|
$0.00M |
|
$0.13M |
|
$1.91M |
|
$10.52M |
|
-- |
|
$0.20M |
|
$10.72M |
|
$-8.81M |
|
$-8.81M |
|
$-8.81M |
|
26.02M |
|
| Cash Flow Statement Financials | |
$-8.98M |
|
$-0.78M |
|
$11.03M |
|
$0.06M |
|
$1.34M |
|
$1.28M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.17 |
|
-- |
|
-- |
|
-- |
|
-0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1.29% |
|
-1.29% |
|
5.93% |
|
-1.29% |
|
$-0.34 |
|
$-0.39 |
|
$-0.39 |
|